Clinical trials: Gastrointestinal Tolerance
Cystic Fibrosis
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation.
- Trial name
- NCT02875366
- Testing
- LUM/IVA
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Gastrointestinal Tolerance
Soy Formula Feedings in Healthy, Term Infants
This study evaluates the GI tolerance and acceptability of soy formulas fed to healthy term infants with reported intolerance to a milk-based formula.
- Trial name
- NCT02456831
- Testing
- Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Abbott Nutrition
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.
Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression.
- Trial name
- NCT00551473
- Testing
- Lavoltidine
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gastrointestinal Tolerance
Gastrointestinal Tolerance of Infant Formula
The study objective is to evaluate the gastrointestinal tolerance of infant formula supplemented with prebiotics.
- Trial name
- NCT02322138
- Testing
- Experimental 1 Infant Formula, Experimental 2 Infant Formula, Reference Group
- Where
- 10 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Hepatitis B, Chronic
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug HEC121120 in Healthy subjects and in patients with chronic hepatitis B
- Trial name
- NCT04536532
- Testing
- HEC121120 tablets, entecavir tablets
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer
Chronic Hepatitis B
Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the reasonable dosage of HRS-5635.
- Trial name
- NCT05808374
- Testing
- HRS-5635
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Gastrointestinal Tolerance
A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber
The purpose of this study is to determine the upper tolerable limit of Sugars from Fiber
- Trial name
- NCT05051202
- Testing
- Sugars from Fiber, Resistant Maltodextrin
- Where
- Ireland
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cambridge Glycoscience
Growth, Tolerance
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT).
- Conditions
- Growth, Tolerance, Adverse Event, Disorder of Intestine
- Trial name
- NEHMO (NCT04055363)
- Testing
- HMO-supplemented infant formula
- Where
- 6 sites in Spain
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Mucositis
Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis
This purpose of this study is to investigate whether ATL-104 is safe and well tolerated, and whether it shows evidence of efficacy in mucositis in patients undergoing PBSCT
- Trial name
- NCT00163280
- Testing
- ATL-104
- Where
- 8 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Alizyme
Celiac Disease
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease
- Trial name
- NCT00889473
- Testing
- Larazotide acetate, Gluten 900 mg
- Where
- 15 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- 9 Meters Biopharma, Inc.
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin.
- Conditions
- Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT01764477
- Testing
- PRI-724
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prism Pharma Co., Ltd.
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Healthy, Hepatic Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants.
- Trial name
- NCT06190691
- Testing
- Pirtobrutinib
- Where
- 8 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Gastrointestinal Tolerance
Evaluation of Infants Fed an Extensively Hydrolyzed Hypo Allergenic Infant Formula
The purpose of this study is to evaluate the growth and compliance of an intended use population of infants receiving an extensively hydrolyzed infant formula.
- Trial name
- NCT03597113
- Where
- 46 sites in Turkey (Türkiye)
- Volunteers
- 320 people
- Sponsor
- Abbott Nutrition
Ulcerative Colitis
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
This is a Phase Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and efficacy of AK101 in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT06281704
- Testing
- AK101 IV, AK101 SC, AK101 IV/AK101 SC
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Akeso
Ulcerative Colitis
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with…
- Trial name
- NCT00628433
- Testing
- HE3286
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Harbor Therapeutics